XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.1
ADDITIONAL BALANCE SHEET DETAIL - Summary of Accrued Expenses and other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Product revenue allowances $ 27,451 $ 15,727
Product return reserves, current portion 5,186 5,295
Clinical trial costs 773 1,885
Compensation and related benefits 5,673 9,194
Operating lease liabilities, current portion $ 5,514 $ 5,400
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
Royalties due to Panion & BF Biotech, Inc. $ 3,267 $ 3,543
Professional fees 1,035 1,452
Accrued manufacturing costs 1,580 1,468
Restructuring costs 251 489
BioVectra, Inc. termination fees 4,894 7,204
Liability related to sale of future royalties, current portion 2,048 2,039
Settlement royalties liability, current portion 10,577 5,924
Other 3,088 3,840
Total accrued expenses and other current liabilities $ 71,337 $ 63,460